ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Leukemia & Lymphoma

Leukemia & Lymphoma

Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor–relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia.

Global inequities in childhood leukemia survival have narrowed in recent years but still persist, according to data from CONCORD-2.

Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation.

Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.

Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension.

The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery.

Patients who have survived Hodgkin lymphoma were at more than double the risk for diagnosis with a second cancer, according to the results of a recent study.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.